Povorcitinib for Hidradenitis Suppurativa: CHMP Recommends Povofortay
November 17, 2026


The Committee for Medicinal Products for Human Use (CHMP) has recommended povorcitinib for hidradenitis suppurativa under the brand name Povofortay.
The opinion was adopted on 17 September 2026, one of twelve new medicines that received positive opinions at the CHMP September 2026 meeting. The applicant is Incyte Biosciences Distribution B.V., and the tablets will come in 45 mg and 75 mg film-coated strengths.
Who povorcitinib for hidradenitis suppurativa is for
The indication is active moderate to severe hidradenitis suppurativa (acne inversa) in adults who have responded inadequately to, or who are intolerant or contraindicated to, anti-TNF therapy. Povorcitinib is a JAK1 inhibitor. The summary says it reduces the number of skin lesions and pain compared with placebo in patients previously treated with anti-TNF therapy. The most common side effects are upper respiratory tract infections, folliculitis, urinary tract infection, hyperlipidaemia, headache, acne and blood creatine phosphokinase increased.
Why it matters
The summary reports a benefit over placebo but gives no trial figures, so the size of that effect is not covered here. The European Commission still has to decide. The summary says that decision normally comes 67 days after the opinion, and detailed recommendations for use will be in the SmPC, published after authorisation. Background reading on the same class is in our coverage of abrocitinib, a JAK1-selective inhibitor, and of Sonelokimab, MoonLake’s candidate for HS.
Source: European Medicines Agency, Povofortay EPAR page and CHMP summary of opinion
Let Google know we are your trusted source.
Add our editorial as a preferred source in your search results.
Value Science Weekly
The week in health technology assessment, market access and health economics — what moved, and what it means.




